In Boc solid-phase peptide synthesis, L-aspartic acid-β-methyl ester hydrochloride is introduced as the side-chain protected C-terminal L-aspartic acid residue after conversion to Boc-L-aspartic acid-β-methyl ester. The β-methyl ester group remains intact under hydrogen fluoride cleavage, which is the standard deprotection step for benzyl-based side-chain protection in Boc chemistry. The hydrochloride is dissolved in deionized water at 0.8–1.0 mol/L and neutralized with sodium bicarbonate 1.2–1.5 eq. Boc anhydride 1.1–1.3 eq in tetrahydrofuran is added over 45–60 min at 0–5 °C. The pH is maintained at 8.5–9.0 with 20% w/v aqueous sodium carbonate for 6–10 h. After acidification to pH 2.5 with 1 M potassium hydrogen sulfate, the N-protected acid is extracted into ethyl acetate, washed with brine, dried over sodium sulfate, and crystallized from ethyl acetate/n-heptane. The isolated Boc-L-aspartic acid-β-methyl ester shows water content below 0.5% by Karl Fischer titration (Ph. Eur. 2.5.12).

For resin loading, a chloromethylated polystyrene-divinylbenzene resin with crosslink density 1% DVB and substitution 0.8–1.2 mmol/g is charged into a low dead-volume solid-phase synthesis vessel fitted with a polytetrafluoroethylene sintered frit and overhead agitation. Boc-L-aspartic acid-β-methyl ester 1.2–1.5 eq relative to resin chloride is converted to the cesium salt with cesium bicarbonate 1.3–1.6 eq in anhydrous N,N-dimethylformamide. The slurry is agitated at 50 °C for 18–24 h. Final substitution is controlled at 0.6–0.9 mmol/g by weight gain or by quantification of released chloride. Unreacted resin chloride is capped with benzyl alcohol. Chain extension from the resin-bound Asp residue uses HBTU and DIPEA at a ratio of 1.0:2.0 relative to the free amino component in N,N-dimethylformamide. Coupling temperature is held at 20–25 °C for 60–90 min, and a Kaiser test is used to confirm free amine consumption. Peptide chain assembly is performed in the same vessel with intermittent N,N-dimethylformamide washes and 2% v/v 1-hydroxybenzotriazole in N,N-dimethylformamide as an additive.

Cleavage from the resin uses hydrogen fluoride:anisole 9:1 v/v at −5 to 0 °C for 45–60 min in a polychlorotrifluoroethylene reactor. The β-methyl ester survives this condition; if the final L-aspartyl residue must be the free acid, saponification is performed after cleavage with 0.2 M sodium hydroxide in dioxane:water 1:1 v/v at 0–5 °C for 20–40 min. The terminal products include peptide active pharmaceutical ingredients containing L-aspartyl residues, such as teriparatide, exenatide, and bivalirudin. Common release tests are HPLC purity (Ph. Eur. 2.2.29), peptide content by amino acid analysis, residual solvents by USP <467>, and bacterial endotoxins by USP <85>. Manufacturing of peptide APIs from this building block must comply with ICH Q7 and ICH Q11.

What Limits Coupling Efficiency in Solution-Phase Peptide API Synthesis with L-Aspartic Acid-β-methyl Ester Hydrochloride?

The limiting variables are residual water, base strength, and α-carbon acidity. When the hydrochloride is used as the C-terminal fragment in a solution-phase peptide coupling, the free α-amino function is neutralized in situ with N-methylmorpholine; an over-base condition above pH 8.0 promotes oxazolone formation at the carboxyl donor and increases the D-aspartyl impurity. A reproducible charge ratio is N-protected amino acid 1.0 eq, 1-hydroxybenzotriazole hydrate 1.10–1.20 eq, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 1.05–1.10 eq, and L-aspartic acid-β-methyl ester hydrochloride 1.0 eq, with N-methylmorpholine 1.05–1.15 eq. The solvent is dichloromethane:dimethylformamide 4:1 v/v. The mixture is held at 0–5 °C for 30 min and then at 20–25 °C for 6–12 h.

Residual water above 0.3% in the combined solvent system, measured by Karl Fischer analysis, hydrolyzes the carbodiimide and reduces conversion. Coupling efficiency is monitored by thin-layer chromatography or in-process HPLC with a C18 column and a mobile phase of 0.1% v/v trifluoroacetic acid in water and acetonitrile. The D-aspartyl epimer is controlled by adding 1-hydroxybenzotriazole and keeping the free base stoichiometry below 1.2 eq. The reaction is conducted in a jacketed glass reactor with a retreat-blade impeller tip speed of 1.3–1.8 m/s and a bottom drain. Work-up uses ethyl acetate extraction, sequential washes with 0.5 M hydrochloric acid, saturated sodium bicarbonate, and brine, followed by drying over sodium sulfate. The isolated protected dipeptide is crystallized from ethyl acetate/n-heptane. Release tests include HPLC purity not less than 99.0% area, chiral HPLC D-isomer not more than 0.10%, and residual solvent by USP <467>. The product is a protected dipeptide fragment for peptidomimetic protease inhibitor synthesis. Compliance with ICH Q7 and ICH Q11 is required for API starting materials. Operational boundary: coupling with amine-based additives is avoided at temperatures above 30 °C because the β-methyl ester can undergo aminolysis.

Chiral-pool conversion to N-protected L-aspartic acid β-methyl ester derivatives is performed under two-phase Schotten-Baumann conditions. For Fmoc protection, L-aspartic acid-β-methyl ester hydrochloride 1.0 eq is dissolved in 10% w/v sodium carbonate solution and cooled to 0–10 °C. Fmoc-O-succinimide 1.05–1.15 eq in 1,4-dioxane is added over 45–60 min. A pH-stat controller maintains pH 8.5–9.0 with 20% w/v sodium carbonate. The mixture is stirred for 4–8 h at 20–25 °C. After reaction, the aqueous layer is extracted with methyl tert-butyl ether to remove nonpolar impurities, then acidified to pH 2.0–2.5 with 6 M hydrochloric acid and extracted with ethyl acetate. The organic phase is washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure at 25–30 °C. Crystallization from ethyl acetate/n-heptane yields Fmoc-L-aspartic acid-β-methyl ester as a white solid. HPLC purity is not less than 99.0% area by Ph. Eur. 2.2.29. Residual Fmoc-O-succinimide-derived impurities are limited to not more than 0.5%. The same equipment train can be used for Cbz protection with benzyl chloroformate 1.0–1.1 eq at pH 9.0–9.5. For Boc protection, Boc anhydride is used under nitrogen in tetrahydrofuran:water 1:1 v/v with pH 8.5–9.0.

These protected building blocks are supplied to medicinal chemistry laboratories and custom peptide manufacturers as Fmoc-, Boc-, or Cbz-L-aspartic acid β-methyl esters. They are used to assemble solution-phase fragments and to introduce L-aspartyl residues at internal positions without premature side-chain ionization. Documentation includes certificate of analysis, residual solvent data by USP <467>, and storage recommendations at 2–8 °C in sealed containers. Distribution of these intermediates within the European Economic Area requires REACH registration or exemption according to the relevant tonnage band. Quality management systems are usually certified to ISO 9001:2015. The terminal products are not finished drugs but protected amino acid derivatives that enter the registered starting material supply chain.

Poly(β-methyl-L-aspartate) via N-Carboxyanhydride Ring-Opening Polymerization

Polymer-grade monomer is obtained by neutralizing L-aspartic acid-β-methyl ester hydrochloride with triethylamine 1.0–1.2 eq in anhydrous tetrahydrofuran at 0–5 °C. Triphosgene 0.35–0.45 eq is added as a tetrahydrofuran solution over 60–90 min. The suspension is heated to 40–50 °C for 2–4 h under a nitrogen sweep. The resulting β-methyl-L-aspartic acid N-carboxyanhydride is precipitated into n-heptane, dissolved in ethyl acetate, washed with ice-cold water, dried over magnesium sulfate, and vacuum-dried at 30 °C for 24 h. Purity by ¹H NMR and HPLC is typically not less than 99.5%. Residual chloride from the hydrochloride starting material is controlled below 500 ppm because chloride can initiate polymerization during storage. The monomer is stored at −20 °C under argon in sealed amber glass bottles.

Ring-opening polymerization is performed in anhydrous N,N-dimethylacetamide with n-hexylamine as initiator. The monomer:initiator molar ratio is set between 50:1 and 200:1. Polymerization proceeds at 25–30 °C for 48–72 h under argon in a jacketed glass reactor with a stainless steel anchor impeller. Water in the solvent is maintained below 50 ppm by Karl Fischer analysis before charge. Poly(β-methyl-L-aspartate) is precipitated into cold diethyl ether, collected, and dried at 35 °C under vacuum to constant mass. Gel permeation chromatography with poly(methyl methacrylate) calibration gives number-average molar mass from 12,000 g/mol to 45,000 g/mol and dispersity from 1.05 to 1.25. End products include biodegradable coatings for drug-eluting implants and porous scaffolds for tissue engineering. Tensile properties of solvent-cast screening films are determined according to ASTM D638-14, Type V specimens, at 23±2 °C and 50±5% RH. Biological evaluation follows ISO 10993-1; quality system requirements follow ISO 13485. The methyl ester side chain is susceptible to alkaline hydrolysis above pH 8.5; this boundary is exploited in the subsequent hydrogel-forming segment.

For α-L-aspartyl-L-phenylalanine methyl ester synthesis, the β-methyl ester acts as a temporary side-chain carboxyl protecting group because the α-carboxyl must be activated selectively without forming aspartimide. L-aspartic acid-β-methyl ester hydrochloride 1.0 eq is N-formylated with formic acid 3.0–5.0 eq and acetic anhydride 1.2–1.5 eq at 5–10 °C for 4–6 h. The N-formyl-L-aspartic acid β-methyl ester is isolated by ethyl acetate extraction and concentrated at 25–30 °C. The α-carboxyl is activated with thionyl chloride 1.1–1.3 eq in dichloromethane at −5 to 0 °C in a glass-lined reactor with retreat-blade impeller. The acid chloride solution is added to L-phenylalanine methyl ester hydrochloride 1.0 eq and triethylamine 2.1–2.3 eq in dichloromethane at 5–10 °C over 60–90 min.

The resulting N-formyl-β-methyl aspartame intermediate is washed with water, 0.5 M hydrochloric acid, and saturated sodium bicarbonate. The β-methyl ester is hydrolyzed with sodium hydroxide 0.5 M in methanol:water 1:1 v/v at 0–5 °C for 30–60 min. The pH is maintained below 10.0 to avoid racemization at the α-carbon. N-deformylation is then performed under acidic conditions, and the crude product is crystallized from water:methanol. The final product must conform to the aspartame monograph limits shown below and to applicable food additive regulations, including FDA 21 CFR 172.804, Commission Regulation (EU) No 231/2012, and Joint FAO/WHO Expert Committee on Food Additives specifications. Industrial yield data for this exact activation sequence are limited; the route is therefore scaled only after pilot validation of the acid chloride step. End product is α-L-aspartyl-L-phenylalanine methyl ester for intense sweetener formulations.

When Poly(β-methyl-L-aspartate) Is Aminolyzed into Poly(hydroxyethyl aspartamide) Hydrogels, Molar Substitution Governs Swelling

Poly(β-methyl-L-aspartate) is converted into a hydrophilic poly(hydroxyethyl aspartamide) network by aminolysis with 2-aminoethanol. The methyl ester repeat unit 1.0 eq is dissolved in anhydrous N,N-dimethylformamide at 8–12% w/v. 2-Aminoethanol 5.0–20.0 eq is added, and the solution is stirred at 50–60 °C for 12–24 h under nitrogen. The reactor is a jacketed cylindrical vessel with an anchor impeller and a reflux condenser. Molar substitution of hydroxyethyl aspartamide units is controlled between 70% and 95% by ¹H NMR integration of the methyl ester singlet against the hydroxyethyl methylene signals. Unreacted 2-aminoethanol is removed by dialysis using a membrane with molecular weight cut-off 3,500 g/mol against deionized water for 48 h; the retentate is lyophilized for 48–72 h at 0.05 mbar.

Hydrogel formation is accomplished by adding a difunctional crosslinker to selected batches or by taking advantage of residual methyl ester groups that are subsequently hydrolyzed to carboxylic acid moieties. Swelling in phosphate-buffered saline at 37 °C is determined gravimetrically after 24 h; reported equilibrium swelling values are formulation-dependent, and published data for this specific intermediate are limited. The resulting hydrogels are used as depots for controlled-release drug delivery and as cell-ingrowth scaffolds. Chemical characterization follows ISO 10993-18; biological evaluation follows ISO 10993-1; quality management follows ISO 13485. The process boundary is residual 2-aminoethanol, which is controlled to not more than 10 ppm by gas chromatography–mass spectrometry before release for medical device use. Incompatibility: the precursor polymer is stored dry at 2–8 °C; exposure to ambient humidity above 60% RH causes surface tack and premature ester hydrolysis.